Table 2.
Results of the univariate Cox analysis
| Parameter | HR (95% CI) | P-value |
|---|---|---|
| Age (years) | 0.99 (0.97–1.02) | 0.54 |
| Female gender | 0.97 (0.54–1.74) | 0.92 |
| Complex lesion | 0.81 (0.46–1.44) | 0.48 |
| Down syndrome | 0.72 (0.39–1.35) | 0.31 |
| Weight (kg) | 0.98 (0.96–1.01) | 0.23 |
| Height (cm) | 0.98 (0.96–1.00) | 0.054 |
| Resting SpO2 (%) | 0.95 (0.92–0.98) | 0.0015 |
| NYHA Class > II | 0.75 (0.42–1.33) | 0.33 |
| 6-MWT distance (m) | 1.00 (0.99–1.00) | 0.14 |
| Larger centre of carea | 0.53 (0.30–0.97) | 0.04 |
| DTT | 0.30 (0.17–0.54) | 0.0001 |
| Diuretics | 1.01 (0.55–1.85) | 0.97 |
| Digoxin | 1.59 (0.85–2.98) | 0.14 |
| ACE-i/ARBs | 1.30 (0.52–3.29) | 0.58 |
| β-Blocker | 0.35 (0.13–1.00) | 0.051 |
| Oral anticoagulation | 1.07 (0.52–2.22) | 0.86 |
| Aspirin | 0.93 (0.47–1.82) | 0.83 |
DTT, disease targeting therapies.
aLarger centre of care was defined as the top four contributors of patients to the register.